文献速递肝病

英国PBC与GLOBE评分系统在中国原发性胆汁性胆管炎患者中的风险预测价值:抗gp210抗体的附加效应

The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
PubMed 文献 · Aliment Pharmacol Ther · 2017-01-13

该研究回顾性分析了2004年9月至2016年5月间276例原发性胆汁性胆管炎(PBC)患者,旨在验证英国PBC(UK-PBC)和GLOBE评分系统在中国人群中的预后价值,并探讨抗gp210抗体的作用。结果显示UK-PBC和GLOBE评分对5年预后有良好预测价值,在抗gp210阳性患者中更佳;抗gp210抗体与更严重的胆汁淤积表现和更差的长期预后相关,可能进一步优化评分系统。

要点

  • UK-PBC和GLOBE评分可良好预测中国PBC患者5年预后,抗gp210阳性者中预测价值更高。
  • 抗gp210阳性患者5年无不良结局生存率低于阴性患者(70% vs 85%,P=0.005)。
  • 抗gp210抗体与更严重胆汁淤积表现和更差长期预后相关,可能优化UK-PBC和GLOBE评分。

核心结论

  • UK-PBC和GLOBE评分系统是中国PBC患者良好的5年预后预测工具,尤其在抗gp210阳性患者中。
  • 抗gp210抗体作为生物标志物与更严重的胆汁淤积表现和更差的长期预后相关。
  • 抗gp210抗体可被添加以进一步优化UK-PBC和GLOBE评分系统。

研究设计与样本

  • 回顾性分析2004年9月至2016年5月间评估的276例PBC患者,包括133例抗gp210阳性和143例抗gp210阴性患者。
  • 使用UK-PBC和GLOBE评分系统评估长期预后。

主要发现

  • 抗gp210阳性 vs 抗gp210阴性患者的5年无不良结局生存率分别为70%和85%(P=0.005)。
  • 肝硬化(P=0.001)、白蛋白水平≤40 g/L(P=0.011)和血小板计数≤153×10^9(P<0.001)与抗gp210抗体作为风险因素具有叠加效应。
  • UK-PBC评分系统:所有PBC患者(n=223)的AUROC为0.924,抗gp210阳性患者(n=110)为0.940,抗gp210阴性患者(n=113)为0.888。
  • GLOBE评分系统:所有PBC患者(n=223)的AUROC为0.901,抗gp210阳性患者(n=110)为0.924,抗gp210阴性患者(n=113)为0.848。
  • UK-PBC评分>0.0578(P<0.001,HR:32.736,95%CI:11.368-94.267)和GLOBE评分<0.850(P<0.001,HR:18.763,95%CI:7.968-44.180)与全队列更差结局相关。

关键数值与推荐

  • UK-PBC评分>0.0578与更差结局相关(P<0.001,HR:32.736,95%CI:11.368-94.267)。
  • GLOBE评分<0.850与更差结局相关(P<0.001,HR:18.763,95%CI:7.968-44.180)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. AIM: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. METHODS: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210- patients. RESULTS: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210- patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210- patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210- patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368-94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968-44.180) were associated with poorer outcomes in the whole cohort. CONCLUSIONS: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yang F, Yang Y, Wang Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther. 2017. PMID: 28083929. doi:10.1111/apt.13927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。